|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPS27L |
Gene summary for RPS27L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPS27L | Gene ID | 51065 |
| Gene name | ribosomal protein S27 like | |
| Gene Alias | RPS27L | |
| Cytomap | 15q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0000028 | UniProtAcc | Q71UM5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51065 | RPS27L | GSM4909282 | Human | Breast | IDC | 2.41e-37 | 5.31e-01 | -0.0288 |
| 51065 | RPS27L | GSM4909285 | Human | Breast | IDC | 1.07e-04 | -3.16e-01 | 0.21 |
| 51065 | RPS27L | GSM4909286 | Human | Breast | IDC | 2.02e-15 | -4.58e-01 | 0.1081 |
| 51065 | RPS27L | GSM4909288 | Human | Breast | IDC | 6.50e-03 | -3.60e-01 | 0.0988 |
| 51065 | RPS27L | GSM4909293 | Human | Breast | IDC | 2.70e-05 | -4.18e-01 | 0.1581 |
| 51065 | RPS27L | GSM4909294 | Human | Breast | IDC | 5.89e-06 | -3.11e-01 | 0.2022 |
| 51065 | RPS27L | GSM4909296 | Human | Breast | IDC | 4.46e-11 | -1.36e-01 | 0.1524 |
| 51065 | RPS27L | GSM4909297 | Human | Breast | IDC | 1.26e-28 | -4.87e-02 | 0.1517 |
| 51065 | RPS27L | GSM4909299 | Human | Breast | IDC | 2.51e-17 | 4.03e-01 | 0.035 |
| 51065 | RPS27L | GSM4909301 | Human | Breast | IDC | 8.22e-13 | 3.19e-01 | 0.1577 |
| 51065 | RPS27L | GSM4909302 | Human | Breast | IDC | 5.61e-07 | 2.18e-01 | 0.1545 |
| 51065 | RPS27L | GSM4909303 | Human | Breast | IDC | 1.89e-04 | 3.52e-01 | 0.0438 |
| 51065 | RPS27L | GSM4909307 | Human | Breast | IDC | 3.29e-51 | 6.33e-01 | 0.1569 |
| 51065 | RPS27L | GSM4909308 | Human | Breast | IDC | 2.07e-58 | 7.12e-01 | 0.158 |
| 51065 | RPS27L | GSM4909309 | Human | Breast | IDC | 1.25e-03 | 1.45e-01 | 0.0483 |
| 51065 | RPS27L | GSM4909311 | Human | Breast | IDC | 9.17e-47 | -2.01e-01 | 0.1534 |
| 51065 | RPS27L | GSM4909312 | Human | Breast | IDC | 1.56e-11 | -2.72e-02 | 0.1552 |
| 51065 | RPS27L | GSM4909313 | Human | Breast | IDC | 1.77e-03 | 2.54e-02 | 0.0391 |
| 51065 | RPS27L | GSM4909315 | Human | Breast | IDC | 1.04e-09 | -4.62e-01 | 0.21 |
| 51065 | RPS27L | GSM4909319 | Human | Breast | IDC | 8.85e-66 | 3.13e-02 | 0.1563 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022618110 | Oral cavity | LP | ribonucleoprotein complex assembly | 125/4623 | 220/18723 | 1.76e-24 | 6.91e-22 | 125 |
| GO:0097193110 | Oral cavity | LP | intrinsic apoptotic signaling pathway | 146/4623 | 288/18723 | 9.76e-22 | 2.78e-19 | 146 |
| GO:0045862110 | Oral cavity | LP | positive regulation of proteolysis | 165/4623 | 372/18723 | 5.40e-17 | 8.46e-15 | 165 |
| GO:0042255110 | Oral cavity | LP | ribosome assembly | 44/4623 | 61/18723 | 8.20e-15 | 1.05e-12 | 44 |
| GO:0042274110 | Oral cavity | LP | ribosomal small subunit biogenesis | 48/4623 | 73/18723 | 1.42e-13 | 1.35e-11 | 48 |
| GO:2000116110 | Oral cavity | LP | regulation of cysteine-type endopeptidase activity | 109/4623 | 235/18723 | 3.16e-13 | 2.91e-11 | 109 |
| GO:0043281110 | Oral cavity | LP | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 99/4623 | 209/18723 | 7.89e-13 | 6.68e-11 | 99 |
| GO:0052547110 | Oral cavity | LP | regulation of peptidase activity | 177/4623 | 461/18723 | 3.01e-11 | 2.00e-09 | 177 |
| GO:0045727110 | Oral cavity | LP | positive regulation of translation | 68/4623 | 136/18723 | 1.53e-10 | 8.51e-09 | 68 |
| GO:0052548110 | Oral cavity | LP | regulation of endopeptidase activity | 164/4623 | 432/18723 | 4.33e-10 | 2.20e-08 | 164 |
| GO:0006417110 | Oral cavity | LP | regulation of translation | 175/4623 | 468/18723 | 4.49e-10 | 2.22e-08 | 175 |
| GO:0034250110 | Oral cavity | LP | positive regulation of cellular amide metabolic process | 76/4623 | 162/18723 | 6.11e-10 | 2.97e-08 | 76 |
| GO:0010952110 | Oral cavity | LP | positive regulation of peptidase activity | 88/4623 | 197/18723 | 6.52e-10 | 3.14e-08 | 88 |
| GO:000863019 | Oral cavity | LP | intrinsic apoptotic signaling pathway in response to DNA damage | 51/4623 | 99/18723 | 8.01e-09 | 3.20e-07 | 51 |
| GO:0010950110 | Oral cavity | LP | positive regulation of endopeptidase activity | 79/4623 | 179/18723 | 9.34e-09 | 3.62e-07 | 79 |
| GO:0072331110 | Oral cavity | LP | signal transduction by p53 class mediator | 72/4623 | 163/18723 | 3.99e-08 | 1.41e-06 | 72 |
| GO:000734614 | Oral cavity | LP | regulation of mitotic cell cycle | 163/4623 | 457/18723 | 7.64e-08 | 2.56e-06 | 163 |
| GO:0000028110 | Oral cavity | LP | ribosomal small subunit assembly | 16/4623 | 19/18723 | 8.23e-08 | 2.73e-06 | 16 |
| GO:004477215 | Oral cavity | LP | mitotic cell cycle phase transition | 150/4623 | 424/18723 | 4.38e-07 | 1.23e-05 | 150 |
| GO:0072332110 | Oral cavity | LP | intrinsic apoptotic signaling pathway by p53 class mediator | 39/4623 | 76/18723 | 5.10e-07 | 1.40e-05 | 39 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0517145 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
| hsa0301045 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
| hsa0517155 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
| hsa0301055 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPS27L | SNV | Missense_Mutation | c.70C>A | p.Leu24Ile | p.L24I | Q71UM5 | protein_coding | deleterious(0.02) | possibly_damaging(0.569) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPS27L | SNV | Missense_Mutation | c.163N>A | p.Leu55Ile | p.L55I | Q71UM5 | protein_coding | tolerated(0.13) | possibly_damaging(0.788) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| RPS27L | SNV | Missense_Mutation | novel | c.216A>C | p.Arg72Ser | p.R72S | Q71UM5 | protein_coding | deleterious(0.01) | possibly_damaging(0.571) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPS27L | SNV | Missense_Mutation | novel | c.63G>T | p.Lys21Asn | p.K21N | Q71UM5 | protein_coding | tolerated(0.1) | possibly_damaging(0.675) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |